Aligos Therapeutics, Inc. cotiza a 5.53 USD y tiene una capitalización bursátil de $35M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunc…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.14 | $-2.21 | $-1.91 |
| Estimado | $-2.53 | $-1.24 | $-2.25 | $-2.49 |
| Sorpresa | — | +88.7% | +1.8% | +23.3% |
| Métrica | ALGS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -4024.9% | -38.6% | -3986.3% |
| Net Margin | -1106.7% | -33.6% | -1073.2% |
| FCF Margin | — | -13.9% | — |
| ROE | -45.2% | -40.4% | -4.8% |
| ROA | -27.3% | -32.0% | +4.7% |
| Current Ratio | 3.90 | 2.84 | +1.06 |
| Debt / Equity | — | 0.28 | — |